Browse the evidence

Intakes of 7 nutrients, including protein, were adequate at baseline and remained so during caloric restriction.

Practitioners can note that certain nutrient levels can be maintained during CR.

One of two synergist muscles consistently demonstrated higher activity levels during the exercises.

Understanding which muscles are more active can help in designing targeted training programs.

Increased 24-hour urinary potassium is associated with better diet quality, lower BMI, diastolic blood pressure, and heart rate.

Encouraging higher potassium intake may improve overall diet quality and health metrics.

Some patients may require weight loss beyond what lifestyle and behavioral modification can achieve.

Recognize that some patients may need additional interventions beyond lifestyle changes.

Obesity has a compelling influence on fertility and reproductive health.

Healthcare practitioners should consider the impact of obesity on reproductive health when treating patients.

Obesity in females is correlated with menstrual abnormalities, infertility, and complications during gestation.

Clinicians should assess reproductive health in obese female patients.

Tirzepatide has been approved by the FDA for type 2 diabetes in adults as a single dose weekly.

Practitioners can prescribe Tirzepatide for managing type 2 diabetes in adults.

Tirzepatide is in phase 3 development for adults with obesity or overweight with weight-related comorbidity.

Practitioners should be aware of Tirzepatide's potential for treating obesity in clinical settings.

A ≥15% BMI reduction was associated with a 33% reduction in group health insurance payments at year 1.

Employers may see significant healthcare cost savings by supporting weight loss programs for employees.

Employees who lost ≤5% BMI had a 10% reduction in health expenditures.

Even modest weight loss can lead to some healthcare cost reductions.

Parameters of glucose metabolism improved as a result of the course.

Improving glucose metabolism can be a beneficial outcome of weight loss programs.

The course focused on psychological dangers associated with avoiding carbohydrates.

Incorporating psychological support in dietary programs can enhance effectiveness.

Parameters of glucose metabolism improved along with psychological indicators of eating impulses.

Improving glucose metabolism and psychological factors can enhance weight loss strategies.

Early genetic diagnostics can identify the type of obesity and guide therapy options.

Implementing genetic testing can enhance personalized treatment strategies for obesity.

Obesity is a chronic disease with significant physical and psychological impairments.

Practitioners should recognize obesity as a serious chronic condition requiring comprehensive management.

There is increasing acceptance of anti-obesity medications as an adjunct to lifestyle modifications and/or surgery.

Practitioners should consider integrating pharmacotherapy with lifestyle changes and surgical options for comprehensive obesity management.

There is an urgent need for a structured, customized and evidence-based clinical practice guideline for the management of obesity in Bangladesh.

Practitioners should advocate for and implement structured guidelines for obesity management.

GLP-1 agonists improve blood glucose profiles and reduce cardiovascular risk.

GLP-1 agonists can be recommended for improving glycemic control and reducing cardiovascular risks in diabetic patients.

Dual GIP/GLP-1 agonists are more effective in treating obesity than GLP-1 agonists alone.

Consider dual GIP/GLP-1 agonists for potentially better outcomes in obesity treatment.

Patients treated with semaglutide experienced a greater improvement in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS) compared to placebo, with an estimated treatment difference of 7.8 points (P < .001).

Semaglutide may be an effective treatment option for improving heart failure symptoms in obese patients.

Serious adverse events were lower in the semaglutide group (13.3%) compared to the placebo group (26.7%) (P < .001).

Semaglutide may offer a safer treatment option for this patient population.

Ultrasonography is a reliable and affordable tool for measuring fat and muscle mass.

Practitioners can consider ultrasonography for better assessment of body composition in patients.

As muscle mass decreases, the risk of conditions like type 2 diabetes rises.

Addressing muscle mass in obesity management could improve health outcomes.

The current Russian clinical guidelines for the treatment of obesity include drugs such as orlistat, sibutramine, and liraglutide.

Clinicians should be aware of the current guidelines when prescribing treatments for obesity.